Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - AXYS Pharmaceuticals, Inc (NasdaqNM:AXPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  7Earnings Announcement
Location
180 Kimball Way
South San Francisco, CA 94080
Phone: (650) 829-1000
Fax: (650) 829-1001
Email: ir@axyspharm.com
Employees (last reported count): 168
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 14%
·Institutional: 30% (35% of float)
(57 institutions)
·Net Inst. Buying: 2.72M shares (+18.21%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
AXYS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, design and development of therapeutic small molecules that address significant markets with major unmet medical needs. AXYS collaborates with large pharmaceutical companies in discovering therapeutics for chronic diseases for which there are large markets. Currently, the Company has significant collaborations with Aventis Pharmaceuticals Product, Inc. (a subsidiary of Aventis S.A.), Merck & Co. and Bayer A.G. The Company also selectively focuses its own resources on discovering and developing therapeutics for the treatment of various types of cancer and other specialty market therapeutics. The Company has on-going programs in the treatment of autoimmune, inflammatory diseases, and cancers.
More from Market Guide: Expanded Business Description

Financial Summary
AXPH is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic small molecules. For the six months ended 6/30/01, revenues increased 33% to $3.9 million. Net loss from continuing operations before accounting change increased 85% to $32.4 million. Revenues reflect research collaborations with Merck and Aventis. Higher loss reflects a $9.4 million loss in the investment in DPI and the write-off of the investment in Akkadix.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

John Walker, 51
Chairman
$665K
Paul Hastings, 40
Pres, CEO, Director
--  
David Riggs
Sr. VP, CFO
--  
William Newell, 42
Sr. VP, Sec.
244K
Daniel Hoth, M.D., 54
Sr. VP, CMO
157K
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AXPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$2.188
Recent Price$3.47 
52-Week High
on 5-Sep-2000
$8.875
Beta0.50 
Daily Volume (3-month avg)245.5K
Daily Volume (10-day avg)103.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-56.6%
52-Week Change
relative to S&P500
-41.8%
Share-Related Items
Market Capitalization$139.5M
Shares Outstanding40.2M
Float34.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.48 
Earnings (ttm)-$1.62 
Earnings (mrq)-$0.36 
Sales (ttm)$0.21 
Cash (mrq)$0.42 
Valuation Ratios
Price/Book (mrq)2.34 
Price/EarningsN/A 
Price/Sales (ttm)16.21 
Income Statements
Sales (ttm)$7.96M
EBITDA (ttm)-$38.0M
Income available to common (ttm)-$60.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-43.52%
Return on Equity (ttm)-86.27%
Financial Strength
Current Ratio (mrq)2.33 
Debt/Equity (mrq)0.49 
Total Cash (mrq)$16.8M
Short Interest
As of 8-Aug-2001
Shares Short363.0K
Percent of Float1.0%
Shares Short
(Prior Month)
529.0K
Short Ratio3.21 
Daily Volume113.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.